

Wednesday 30 September 2015

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
2015 ANNUAL REPORT HIGHLIGHTS**

Genera Biosystems Limited (**‘Genera’**) is pleased to present its Final Report for the financial year ended 30 June 2015.

Genera continued to grow AmpaSand® product sales with revenue increasing to \$344,728 up 68.4% on the previous corresponding period (‘pcp’). Other income grew 114.2% versus pcp to \$967,204. Subsequent to 30 June, and through to the date of this report, a further \$252,824 of AmpaSand product sales have been made and the company presently anticipates that it will surpass full year 2015 sales during the December quarter.

The company reported a net loss of \$2,789,474, compared to a net loss of \$2,461,958 in the previous year, largely reflecting increased notional ‘non-cash’ financing costs from options issued in lieu of loan interest and the \$2.5m Series B convertible notes issued during the period. No cash interest is payable on the Series B notes in the event that they are converted into ordinary shares.

Cash used in operating activities increased to \$956,392 up 13% compared to \$846,265 in the previous year. The company ended the year with cash of \$1,486,582, its highest year-end cash balance since 2011.

Genera’s AmpaSand multiplexing molecular diagnostic platform continues to prove itself to be world class and is a genuine multiplexing platform for plate based assays, which are the most common format for high throughput MDx assays used by pathology laboratories. With AmpaSand®, 1 well of a plate can deliver 1 multiplexed assay testing for between 5 and 150 targets from a single sample, performance characteristics which no Real-Time PCR approach can match.

Operating highlights for the financial year and to the date of this report include:

- Record and continuing strong AmpaSand assay sales growth;
- Successful ARTG listing of the PapType® and RTI-plex™ assays and the Q-Plots analytical software;
- CE mark status for both PapType® and RTI-plex allowing for approved commercial use in the 28 member states of the European market and certain parts of Asia;
- Non-exclusive distribution agreement for AmpaSand assay launch into India, gaining access to SRL Diagnostics the leading national lab network in India (first sales late 2015/early2016);
- Scale-up program to deliver 5-fold increase in Scoresby manufacturing capacity well advanced and on track for 2016 implementation;
- The grant of 21 additional patents – Genera now holds a portfolio of approximately 70 granted patents with a further 35 patents pending and new intellectual property continuing to be developed;
- Development finalised of AmpaSand Version 2.1 and due for customer release November 2015 – reduces assay run-time below 5 hours;

- AmpaSand Version 3.0 development commenced and scheduled for release late 2016 – may reduce sample preparation time by 70% and decrease customer reagent costs used in DNA/RNA preparation by over 60% compared to currently available methods;
- New 384-well plate format to be introduced delivering 3.8x increase in volume throughput;
- STIplex™ development further advanced, release due mid-2016 and BBVplex™ late 2016;
- Clinical data from 6,000 patient screening study for PapType HPV test received with assay performance consistent with prior studies – the study was a head-to-head comparison of PapType and six commercially available HPV tests from leading global IVD companies;
- PapType to be included in a prestigious ~2,000 patient *prospective* HPV clinical study from a screening setting in the United States – following this study PapType® will have independent clinical performance data from Australia, the UK and the US involving six different studies utilising approximately 11,000 clinical patient samples;
- Scientific Advisory Board to be re-established constituting leading *global* key opinion leaders in HPV screening from Australia, the UK and the US.
- Successful integration with two global IVD companies instrumentation systems, with both proving to be the most reliable and high performance systems that Genera has worked with to date; and
- Continued discussions to deliver appropriately structured global IVD partnership before end of 2015, ideally aiming for completion prior to Genera November 2015 AGM.

Genera Chief Executive Officer, Richard Hannebery said, “There is no doubt that the past 12 months has been the most productive year in Genera’s history with a lot of things which have been planned for a long period of time slotting into place. This is the result of the hard work of our small but highly capable team executing our clear plan very well. The foundation is now laid and with some further well-considered execution, and some more hard work, the Genera team looks forward to delivering the outstanding outcome that our shareholders deserve.”

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems: Genera Biosystems Limited (“GBI”) is an Australian Stock Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests. GBI has successfully developed two products to date, PapType® and RTI-Plex™, both of which are CE-IVD approved with several additional products in the company’s development pipeline. Genera manufactures these products in its Therapeutics Goods Administration (TGA) certified manufacturing facility in Scoresby, Victoria, Australia.